1
|
LIEBERMAN K, Paredes A, Srivastava T, Komers R, Murphy E, Trachtman H. WCN23-1184 LONG-TERM EFFICACY AND SAFETY OF SPARSENTAN IN YOUNG PATIENTS WITH FSGS: 240-WEEK ANALYSIS OF THE DUET OPEN-LABEL EXTENSION (OLE). Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
2
|
Bernabé-Caro R, García-Campelo R, Garrido P, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres J, Majem M, Diz P, Gordo R, Coca M, de Castro J. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Boni V, Pistilli B, Braña I, Shapiro GI, Trigo J, Moreno V, Castellano D, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Antón A, Paredes A, Huidobro G, Subbiah V. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open 2022; 7:100571. [PMID: 36037567 PMCID: PMC9588879 DOI: 10.1016/j.esmoop.2022.100571] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 07/21/2022] [Accepted: 07/27/2022] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient models and preliminary clinical activity in BRCA1/2 breast cancer. PATIENTS AND METHODS This phase II basket multitumor trial (NCT02454972) evaluated lurbinectedin 3.2 mg/m2 1-h intravenous infusion every 3 weeks in a cohort of 21 patients with pretreated germline BRCA1/2 breast cancer. Patients with any hormone receptor and human epidermal growth factor receptor 2 status were enrolled. The primary efficacy endpoint was overall response rate (ORR) according to RECIST v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. RESULTS Confirmed partial response (PR) was observed in six patients [ORR = 28.6%; 95% confidence interval (CI) 11.3% to 52.2%] who had received a median of two prior advanced chemotherapy lines. Lurbinectedin was active in both BRCA mutations: four PRs in 11 patients (36.4%) with BRCA2 and two PRs in 10 patients (20.0%) with BRCA1. Median DoR was 8.6 months, median PFS was 4.1 months and median OS was 16.1 months. Stable disease (SD) was observed in 10 patients (47.6%), including 3 with unconfirmed response in a subsequent tumor assessment [ORR unconfirmed = 42.9% (95% CI 21.8% to 66.0%)]. Clinical benefit rate (PR + SD ≥ 4 months) was 76.2% (95% CI 52.8% to 91.8%). No objective response was observed among patients who had received prior poly (ADP-ribose) polymerase inhibitors. The most common treatment-related adverse events (AEs) were nausea (61.9%), fatigue (38.1%) and vomiting (23.8%). These AEs were mostly grade 1/2. The most common grade 3/4 toxicity was neutropenia (42.9%: grade 4, 23.8%: with no febrile neutropenia). CONCLUSIONS This phase II study met its primary endpoint and showed activity of lurbinectedin in germline BRCA1/2 breast cancer. Lurbinectedin showed a predictable and manageable safety profile. Considering the exploratory aim of this trial as well as previous results in other phase II studies, further development of lurbinectedin in this indication is warranted.
Collapse
Affiliation(s)
- V Boni
- START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | - I Braña
- Hospital Universitario Vall D'Hebron (VHIO), Barcelona, Spain
| | | | - J Trigo
- Hospital Universitario Virgen De La Victoria, IBIMA, Málaga, Spain
| | - V Moreno
- START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - D Castellano
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - C Kahatt
- PharmaMar, Colmenar Viejo, Madrid, Spain
| | - V Alfaro
- PharmaMar, Colmenar Viejo, Madrid, Spain
| | - M Siguero
- PharmaMar, Colmenar Viejo, Madrid, Spain
| | - A Zeaiter
- PharmaMar, Colmenar Viejo, Madrid, Spain
| | - F Longo
- Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - K Zaman
- University Hospital CHUV, Lausanne, Switzerland
| | - A Antón
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - A Paredes
- Hospital Universitario Donostia, Donostia-San Sebastián, Spain
| | - G Huidobro
- Hospital Universitario de Vigo Alvaro Cunqueiro, Pontevedra, Spain
| | - V Subbiah
- The University of Texas MD Anderson Cancer Center, Houston, USA.
| |
Collapse
|
4
|
Oliveira CP, Paredes A, Siddiqui M, Serfaty L, Chowdhury A, Stefano JT, Vanni DS, Boyett S, Sanyal AJ. The transcontinental variability of nonalcoholic fatty liver disease. Hepatoma Res 2020; 6:72. [PMID: 36419503 PMCID: PMC9681157 DOI: 10.20517/2394-5079.2020.73] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
AIM To compare the phenotype of lean versus overweight (OW) and obese (OB) subjects with non-alcoholic fatty liver disease (NAFLD) across multiple continents. METHODS A retrospective study of histologically defined subjects from a single center each in France (Fr), Brazil (Br), India (In) and United States (US) was performed. RESULTS A total of 70 lean [body mass index (BMI) < 25 kg/m2] subjects (Fr:Br:In:US: 16:19:22:13) with NAFLD were compared to 136 OW (BMI > 25 kg/m2, BMI < 29 kg/m2) (n = 28:33:52:23) and 224 OB subjects (BMI > 29 kg/m2) (n = 81:11:22:103). Lean French subjects had the lowest incidence of type 2 diabetes while those from Brazil (P < 0.01) had the highest. Lean subjects had similar low-density lipoprotein-cholesterol, but higher high-density lipoprotein-cholesterol compared to obese subjects in all regions. In both lean and obese subjects, there were both insulin-sensitive and insulin-resistant subjects. Lean French subjects were most insulin-sensitive while those from Brazil were mostly insulin-resistant. For each weight category, subjects from India were more insulin-sensitive than those from other regions. Disease activity increased from lean to overweight to obese in France but was similar across weight categories in other regions. CONCLUSION The phenotype of NAFLD in lean subjects varies by region. Some obese subjects with NAFLD are insulin-sensitive. We hypothesize that genetics and region-specific disease modifiers account for these differences.
Collapse
Affiliation(s)
- Claudia P. Oliveira
- Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 01000-000, Brazil
- Laboratório de Gastroenterologia Clínica e Experimental (LIM-07) do Departamento de Gastroenterologia e Hepatologia do Hospital das Clínicas HCFMUSP da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 01000-000, Brazil
| | - Angelo Paredes
- Internal Medicine, Gastroenterology and Hepatology Services, Brooke Army Medical Center, San Antonio, TX 78234, USA
| | - Mohammed Siddiqui
- Div.of Gastroenterology, Hepatology and Nutrition, Dept. of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0341, USA
| | - Lawrence Serfaty
- Viral and Metabolic Liver Unit, Department of Hepatology, Saint-Antoine Hospital, 75012 Paris, Paris
| | - Abhijit Chowdhury
- Department of Hepatology, School of Digestive and Liver Disease, Institute of Post Graduate Medical Education & Research, Kolkata 700020, India
- Disease Biology, John C Martin Centre for Liver Research and Innovations Sonarpur, Kolkata 7000150, India
| | - Jose Tadeu Stefano
- Laboratório de Gastroenterologia Clínica e Experimental (LIM-07) do Departamento de Gastroenterologia e Hepatologia do Hospital das Clínicas HCFMUSP da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 01000-000, Brazil
| | - Denise Siqueira Vanni
- Laboratório de Gastroenterologia Clínica e Experimental (LIM-07) do Departamento de Gastroenterologia e Hepatologia do Hospital das Clínicas HCFMUSP da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 01000-000, Brazil
| | - Sherry Boyett
- Div.of Gastroenterology, Hepatology and Nutrition, Dept. of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0341, USA
| | - Arun J. Sanyal
- Div.of Gastroenterology, Hepatology and Nutrition, Dept. of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0341, USA
| |
Collapse
|
5
|
Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG, Balart L, Borg B, Chalasani N, Charlton M, Conjeevaram H, Fuchs M, Ghalib R, Gholam P, Halegoua-De Marzio D, Harrison S, Jue C, Kemmer N, Kowdley K, Lai M, Lawitz E, Loomba R, Noureddin M, Paredes A, Rinella M, Rockey D, Rodriguez M, Rubin R, Ryan M, Sanyal A, Scanga A, Sepe T, Shiffman M, Shiffman M, Tetri B, Thuluvath P, Torres D, Vierling J, Wattacheril J, Weiland A, Zogg D. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology 2020; 158:1334-1345.e5. [PMID: 31812510 DOI: 10.1053/j.gastro.2019.11.296] [Citation(s) in RCA: 183] [Impact Index Per Article: 45.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Revised: 11/25/2019] [Accepted: 11/27/2019] [Indexed: 12/19/2022]
Abstract
BACKGROUND & AIMS Increased levels of galectin 3 have been associated with nonalcoholic steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypertension in rats and was safe and well tolerated in phase 1 studies. We performed a phase 2b, randomized trial of the safety and efficacy of GR-MD-02 in patients with NASH, cirrhosis, and portal hypertension. METHODS Patients with NASH, cirrhosis, and portal hypertension (hepatic venous pressure gradient [HVPG] ≥ 6 mm Hg) from 36 centers were randomly assigned, in a double-blind manner, to groups that received biweekly infusions of belapectin 2 mg/kg (n = 54), 8 mg/kg (n = 54), or placebo (n = 54) for 52 weeks. The primary endpoint was change in HVPG (Δ HVPG) at the end of the 52-week period compared with baseline. Secondary endpoints included changes in liver histology and development of liver-related outcomes. RESULTS We found no significant difference in ΔHVPG between the 2 mg/kg belapectin group and placebo group (-0.28 mm HG vs 0.10 mm HG, P = 1.0) or between the 8 mg/kg belapectin and placebo group (-0.25 mm HG vs 0.10 mm HG, P = 1.0). Belapectin had no significant effect on fibrosis or nonalcoholic fatty liver disease activity score, and liver-related outcomes did not differ significantly among groups. In an analysis of a subgroup of patients without esophageal varices at baseline (n = 81), 2 mg/kg belapectin was associated with a reduction in HVPG at 52 weeks compared with baseline (P = .02) and reduced development of new varices (P = .03). Belapectin (2 mg/kg) was well tolerated and produced no safety signals. CONCLUSIONS In a phase 2b study of 162 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly infusion of belapectin was safe but not associated with significant reduction in HVPG or fibrosis compared with placebo. However, in a subgroup analysis of patients without esophageal varices, 2 mg/kg belapectin did reduce HVPG and development of varices. ClinicalTrials.gov number: NCT02462967.
Collapse
Affiliation(s)
- Naga Chalasani
- Indiana University School of Medicine, Indianapolis, Indiana.
| | | | | | - Raj Vuppalanchi
- Indiana University School of Medicine, Indianapolis, Indiana
| | | | | | | | - Maxmillan Pyko
- Indiana University School of Medicine, Indianapolis, Indiana
| | | | - Arun Sanyal
- Virginia Commonwealth University, Richmond, Virginia
| | | | | | - Rex Horton
- Galectin Therapeutics Alpharetta, Georgia
| | | | - William Irish
- East Carolina University, Greenville, South Carolina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
De Castro Carpeno J, Felip E, Juan O, Campelo RG, Aguiar D, Terrassa J, Castro RL, Blanco AC, Paredes A, Bernabe R, Barneto I, Campillo J, García-Palacios L, Rojo F. P2.01-10 Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Liane BJ, Dooley G, Sarkar S, Paredes A, Morales-Cardona AL. One-hour Recovery Time in Subjects Undergoing Percutaneous Liver Biopsy: A Quality Improvement and Patient Safety Project. Cureus 2019; 11:e5799. [PMID: 31728246 PMCID: PMC6827865 DOI: 10.7759/cureus.5799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Introduction Liver biopsy is the gold standard in diagnosing, staging and guiding clinical management in liver disease. There are currently no standard guidelines for liver biopsy recovery time. The aims of this project are to study the safety of a one-hour recovery time after percutaneous liver biopsies and to measure the rate of complications and identify risk factors. Methods A total of 500 consecutive subjects who underwent a percutaneous liver biopsy at a single-center teaching institution (Brooke Army Medical Center) were enrolled between December 2016 and October 2018. Biopsies were performed using a 14-gauge Bard® Monopty® core biopsy needle using bedside ultrasound. Complications were defined as: Pain level > 5 out of 10, hospitalizations, emergency department visits, or other. Major complications were defined as: hospitalizations and emergency department visits. Results The only complication that required hospitalization was identified during the first hour of recovery. Liver biopsies of subjects with body mass index (BMI) ≥35 kg/m2 were not associated with more complications when compared to patients less than 30 kg/m2. Using a spinal needle (3.5’’) to anesthetize the liver capsule in subjects with excess subcutaneous tissue did not result in more complications when compared to the standard 1.5’’ needle. Only 3% of the patients who received lidocaine alone for the biopsy required post-procedure medications. Conclusion Ultrasound-guided percutaneous liver biopsies, using a 14-gauge needle, were overall found to be safe. A one-hour post recovery period is adequate to identify all immediate major complications.
Collapse
Affiliation(s)
- Billy-Joe Liane
- Internal Medicine, Brooke Army Medical Center, San Antonio, USA
| | - Guy Dooley
- Gastroenterology and Hepatology, Brooke Army Medical Center, San Antonio, USA
| | - Sonali Sarkar
- Gastroenterology and Hepatology, Brooke Army Medical Center, San Antonio, USA
| | - Angelo Paredes
- Gastroenterology and Hepatology, Brooke Army Medical Center, San Antonio, USA
| | | |
Collapse
|
8
|
Paredes A, Garcia B, Sarria G. Clinical Experience in Large-Sized Surface Treatments with High Dose Rate Brachytherapy (HDR). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Hei AV, Bush K, Fentanes E, Aden J, Paredes A, Harrison S, Thomas D. DIFFUSE CORONARY ATHEROSCLEROSIS AND LESS STABLE PLAQUE MORPHOLOGIES ARE MORE PREVALENT IN ASYMPTOMATIC BIOPSY-PROVEN NAFLD PATIENTS: RESULTS FROM THE PROSPECTIVE PREVALENCE STUDY. J Am Coll Cardiol 2019. [DOI: 10.1016/s0735-1097(19)32443-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
Tiseo M, Santo A, Hochmair M, Geldart T, Metro G, Hanrahan E, Lamberg K, Moran T, Nyhus C, Paredes A, Vansteenkiste J, Vicente D, Miranda M, Rigas J, de Marinis F. ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) - European subset. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Thomas D, Bush K, Prentice R, Ramsey B, Paredes A, Aden JK, Harrison SA. SEVERITY OF BIOPSY-PROVEN NAFLD NOT PREDICTIVE OF PRESENCE OR SEVERITY OF CORONARY ATHEROSCLEROSIS IN ASYMPTOMATIC PATIENTS: RESULTS FROM THE PROSPECTIVE PREVALENCE STUDY. J Am Coll Cardiol 2018. [DOI: 10.1016/s0735-1097(18)32442-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
12
|
Majem Tarruella M, Isla Casado L, Guirado M, Massuti Sureda B, Ortega Granados A, Marse Fabregat R, Domine Gomez M, de las Peñas R, Moran Bueno M, Vazquez Estevez S, Sala Gonzalez M, Coves Sarto J, Sánchez-Torres J, Vicente Baz D, Gonzalez-Larriba J, Paredes A, Farré N, Fernández Fornos L, Mena A, Provencio Pulla M. Preliminar analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): NORA trial (GECP 15/02). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx379.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, Iqbal K, Lenz O, Asif A, Nahar N, Leclerq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida Suarez M, Busse JC, Esquenazi M, Esquenazi A, Garcia Mayol L, Garcia Estrada H. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2016; 14:890-5. [PMID: 16335581 DOI: 10.1191/0961203305lu2238oa] [Citation(s) in RCA: 128] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of this study was to identify the factors associated with important clinical outcomes in a case-control study of 213 patients with lupus nephritis. Included were 47% Hispanics, 44% African Americans and 9% Caucasians with a mean age of 28 years. Fifty-four (25%) patients reached the primary composite outcome of doubling serum creatinine, end-stage renal disease or death during a mean follow-up of 37 months. Thirty-four percent African Americans, 20% Hispanics and 10% Caucasians reached the primary composite outcome ( P < 0.05). Patients reaching the composite outcome had predominantly proliferative lupus nephritis (WHO classes: 30% III, 32% IV, 18% V and 5% II, P < 0.025) with higher activity index score (7 ± 6 versus 5 ± 5, P<0.05), chronicity index (CI) score (4 ± 3 versus 2 ± 2 unit, P<0.025), higher baseline mean arterial pressure (MAP) (111 ± 21 versus 102 ± 14 mmHg, P<0.025) and serum creatinine (1.9 ± 1.3 versus 1.3 ± 1.0 mg/dL, P<0.025), but lower baseline hematocrit (29 ± 6 versus 31 + 5%, P<0.025) and complement C3 (54 ± 26 versus 65 + 33 mg/dL, P<0.025) compared to controls. More patients reaching the composite outcome had nephrotic range proteinuria compared to controls (74% versus 56%, P<0.025). By multivariate analysis, CI (hazard ratio [95% CI] 1.18 [1.07-1.30] per point), MAP (HR 1.02 [1.00-1.03] per mmHg), and baseline serum creatinine (HR 1.26 [1.04-1.54] per mg/dL) were independently associated with the composite outcome. We concluded that hypertension and elevated serum creatinine at the time of the kidney biopsy as well as a high CI are associated with an increased the risk for chronic renal failure or death in patients with lupus nephritis.
Collapse
Affiliation(s)
- G Contreras
- Acute Dialysis Unit Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Martinez E, Oses MR, Casas F, Viñolas N, Minguez J, Paredes A, Casas AP, Domine E. PO-0681: Randomized phase II study of Erlotinib with radiotherapy in irresectable non small cell lung cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31931-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Arriola E, Paredes A, Gomez RG, Diz P, Constenla M, Girón CG, Amador M, Reck M, Vivanco GL. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30257-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Ramirez G, Paredes A, Estacio C, Rojas L, Moreno D, Lazaro M, Vallenas F, Arca JM. First Dengue Outbreak in Villa Maria del Triunfo District, Lima, Peru 2013. Int J Epidemiol 2015. [DOI: 10.1093/ije/dyv096.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Abstract
OBJECTIVES Although effective HCV treatment is available, it can be difficult to access for uninsured, urban patients. Our aim was to assess the utility of evaluation and outcomes in the uninsured with HCV when access to health care and treatment with triple therapy is provided. METHODS We performed a retrospective review of consecutive patients referred for HCV from 2011 to June 2013 to an indigent HCV clinic. The primary outcomes were assessment of disease severity by noninvasive means and initiation of therapy. RESULTS We identified 350 patients: mean age 50.6, 84 % with no insurance, 62 % men, 58 % black, 91 % HCV treatment naïve. Of these, 148 underwent liver biopsy and 68 % had F0-F1 and 10 % had F3-F4 fibrosis. FIB-4 and APRI were highly correlated (r = 0.9; p < .0001) and correctly classified patients by fibrosis strata (F0-F1, F2, and F3-F4; p = .0004). When combined, a FIB-4 ≤1.5 and APRI ≤0.5 correctly classified the absence of advanced disease in 97 % (p < .0001). Of those evaluated, 39 (11 %) went on to HCV treatment. Of those not in a clinical trial, 51 % completed treatment with SVR in 61 % with genotype 1 and 75 % in genotypenon-1. Of those not treated (n = 309), the most common reasons were mild disease (16 %), lost to follow-up (23 %), ongoing alcohol or substance abuse (24 %), and uncontrolled depression (10 %). CONCLUSION Noninvasive assessment can accurately exclude advanced fibrosis. Despite access to care, the utility of evaluating to initiate HCV treatment is low suggesting that eliminating the barrier to health care may not increase HCV treatment.
Collapse
Affiliation(s)
- Indira Donepudi
- Section of Hepatology, Virginia Commonwealth University, 1200 E Broad St, West Hospital, Rm 1478, PO Box 980341, Richmond, VA, 23298-0341, USA
| | | | | | | | | |
Collapse
|
18
|
Borrelli M, Hamilton E, Watanabe F, Paredes A, Hennings L, Culp W. Influence of thrombin content and fibrin complexity on in vitro sonothrombolysis rate and efficacy. J Vasc Interv Radiol 2013. [DOI: 10.1016/j.jvir.2013.01.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
19
|
Oramas J, Cobo M, Paredes A, Arriola E, Sala M, Artal A, Girones R, Martinez M, Figueroa S, Domine M. 9075 POSTER ARIADNA Study – Evaluation of Symptoms on Daily Life and Health-related Quality of Life (HRQoL) of Patients With Advanced Non-small Cell Lung Cancer (NSCLC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72387-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Amweg A, Paredes A, Salvetti N, Lara H, Ortega H. Expression of melanocortin receptors mRNA, and direct effects of ACTH on steroid secretion in the bovine ovary. Theriogenology 2011; 75:628-37. [DOI: 10.1016/j.theriogenology.2010.10.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Revised: 08/27/2010] [Accepted: 09/14/2010] [Indexed: 10/18/2022]
|
21
|
Cobo M, Ferrer N, Paredes A, Mendez M, Muñoz-Langa J, Rueda A, Alvarez De Mon M, Sanchez-Hernandez A, Gallego R, Torrego J. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC): Final report. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Provencio M, Cobo M, Vazquez-Estevez S, Firvida J, Maciá S, Barneto I, Oramas J, Sanchez-Hernandez A, Ferrer N, Paredes A. Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, de Mon MÁ, Sánchez-Hernández A, Gallego R, Torrego J. 9149 Phase II study of bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (p) with metastatic non squamous non-small-cell lung cancer (NSCLC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71862-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with advanced NSCLC other than predominantly squamous cell histology. B has been shown to improve progression free survival (PFS) and overall survival (OS) when combined with cisplatin/gemcitabine and carboplatin/paclitaxel, respectively. However, there are limited data on the safety and efficacy of B in combination with other widely used chemotherapy doublets for NSCLC. This is a single-arm, open- labeled, single-stage phase II trial of cisplatin (C), docetaxel (D) and B for NSCLC. Methods: Eligibility criteria: chemo- naïve, stage IIIB wet or IV, non-squamous NSCLC, PS 0–1, no brain metastases and no history of gross hemoptysis. P received D (75 mg/m2), C (75 mg/m2), and B (15 mg/kg iv) on day 1 every 3 weeks for up to 6 cycles, followed by B 15 mg/kg alone every 3 weeks until disease progression or toxicity. Primary endpoint: PFS. Results: 50 p were enrolled (enrollment completed): 24% female, median age 60 (36–74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 92%. Two p did not start treatment. Median follow-up is 5.3 months (range 0–13.6). Median number of cycles of B was 7 (range 0–18). 56% completed 6 cycles of treatment; 24% received ≥ 12 cycles of B. Most frequent grade ≥ 3 toxicities: diarrhea (14.6%), fatigue (14.6%), dyspnea (9.8%), anorexia (4.9%), alopecia (4.9%), esophagitis (4.9%), constipation (4.9%), mucositis (12.2%), proteinuria (4.9%); hematological toxicities: neutropenia (22%), febrile neutropenia (9.8%), leucopenia (14.6%), lymphopenia (4.9%). Of interest, 41.5% developed grade <3 epistaxis and 17% hypertension (1 p grade 3). One p died due to hemoptysis. 46 p were evaluable for response: 29 PRs (ORR: 63%). 18 of 48 p have experienced progression or death with a median SLP of 7.8 months (95% CI: 6.6-NR). Median OS is 13.5 months (95% CI: 12.7–13.6; 81.2% p censored); 1-year survival is 83.9% (95% CI: 67.4%-92.5%). Conclusions: Treatment with C, D and B, followed by maintenance B in 1st line of advanced non-squamous NSCLC shows an acceptable toxicity profile and promising efficacy. Final results will be presented. [Table: see text]
Collapse
Affiliation(s)
- N. Ferrer
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - M. Cobo
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - A. Paredes
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - M. Méndez
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - J. Muñoz-Langa
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - A. Rueda
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - M. Álvarez de Mon
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - A. Sánchez-Hernández
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - R. Gallego
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - J. Torrego
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| |
Collapse
|
25
|
Federico M, Cunningham B, Paredes A, Lee D, Folio L. Radiology corner. Case 34: Aspergilloma. Mil Med 2009; 174:xv-xvi. [PMID: 19485118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
26
|
Silva H, Nieto R, Montes C, Paredes A, Rentería P, Ramírez A, Jérez S. [Gender-related differences in functional assessment of serotonergic system in healthy young subjects]. Actas Esp Psiquiatr 2008; 36:218-222. [PMID: 18615275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
INTRODUCTION Prolactin stimulation test with serotonergic stimulants has been widely used in the study of diverse psychiatric disorders. However, the characterization of this response in normal subjects is still incomplete. OBJECTIVE To compare the response to serotonin stimulation using dexfenfluramine, a specific serotonergic agent, in young healthy men and women, controlling the menstrual cycle. METHODS A total of 10 women and 9 men, who were given 30 mg of dexfenfluramine orally, were studied and their levels of prolactin were measured on an hourly basis for a five-hour period. Baseline, maximum and delta values of prolactin were compared for both groups. RESULTS According to the age groups studied (mean age for men: 19.9 +/- 2.5 years old; mean age for women: 20 +/- 1.5 years old), the prolactin maximum level and the response to prolactin (DPRL) were significantly higher in women (p-values: 0.02 and 0.04, respectively). CONCLUSIONS Young healthy women show a greater response to stimulation with dexfenfluramine than young healthy men. Clinical and biological implications of this observation are discussed in the context of the currently available research papers.
Collapse
Affiliation(s)
- H Silva
- Clínica Psiquiátrica de la Universidad de Chile. Santiago (Chile).
| | | | | | | | | | | | | |
Collapse
|
27
|
Ferrer N, Paredes A, Muñoz-Langa JM, Mendez M, Cobo M, de-Portugal T, Giner V, Garcia S, Gallego R, Torrego J. Bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (pts) with advanced or metastatic, non squamous, non-small-cell lung cancer (NSCLC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Martinez E, Martinez M, Viñolas N, Casas F, de la Torre A, Valcarcel F, Minguez J, Paredes A, Casas AP, Dómine M. Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: A prospective randomized phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7563] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial. Lung Cancer 2007; 58:238-45. [PMID: 17658655 DOI: 10.1016/j.lungcan.2007.06.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2006] [Revised: 04/02/2007] [Accepted: 06/05/2007] [Indexed: 11/18/2022]
Abstract
PURPOSE We conducted a prospective phase II trial to evaluate the efficacy and toxicity of induction chemotherapy with paclitaxel plus carboplatin followed by concurrent radiotherapy with weekly paclitaxel in stage IIIB non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS Patients with stage IIIB NSCLC received two 3-week cycles of paclitaxel 200mg/m(2) combined with carboplatin (target area under the plasma concentration curve (AUC) of 6 mg/ml) followed by weekly paclitaxel 50mg/m(2) concurrently with radiotherapy consisted of 2 Gy daily, 5 days per week (60 Gy total dose in 6 weeks). The median follow-up period was 5 years. RESULTS Between March 1999 and January 2002, 21 patients were enrolled and analyzed. Ninety percent of patients completed the planned treatment schedule. The overall response rate was 76% (24% complete response and 52% partial response). The median overall survival time was 15 months and the 1-year, 2-year and 5-year overall survival rates were 57, 33 and 24%, respectively. The disease progression rate at 1 year was 43% and the median progression-free survival was 8 months. During the chemoradiation period, grade 3-4 oesophagitis and pneumonitis were observed in 24 and 14% of patients, respectively. CONCLUSIONS Induction chemotherapy with carboplatin and paclitaxel followed by weekly paclitaxel with concurrent radiotherapy was found to be active and tolerable in selected stage IIIB NSCLC patients. Further studies are needed to improve the safety profile and outcome in this setting.
Collapse
Affiliation(s)
- C Pallarés
- Department of Medical Oncology, Sant Pau University Hospital, St. Antoni M(a) Claret 167, 08025 Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- A Paredes
- National Center for Macromolecular Imaging, Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
31
|
Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15:1194-203. [PMID: 15277258 DOI: 10.1093/annonc/mdh319] [Citation(s) in RCA: 237] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Multidrug resistance 1 (MDR1) has been related to antimicrotubule resistance. We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel-cisplatin-treated stage IV NSCLC patients. PATIENTS AND METHODS Using the TaqMan 5' nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 -37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel-cisplatin-treated advanced NSCLC patients. ERCC1 expression was measured in RNA isolated from PBLs using real-time reverse transcriptase PCR. RESULTS Overall median survival was 10.26 months. Median survival was 9.67 months for 34 patients with ERCC1 118 C/T, 9.74 months for 17 patients with T/T, and not reached for 11 patients with C/C (P=0.04). Similar significant differences in time to progression were observed according to ERCC1 118 genotype (P=0.03). No other significant differences were observed. CONCLUSIONS Patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival. ERCC1 SNP assessment could be an important component of tailored chemotherapy trials.
Collapse
Affiliation(s)
- D Isla
- Hospital Clinico Lozano Blesa, Zaragoza, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Garcı́a-Olmo J, De Pedro E, Garrido A, Paredes A, Sanabria C, Santolalla M, Salas J, Garcı́a-Hierro J, Gonzalez I, Garcı́a-Cachan M, Guirao J. Determination of the precision of the fatty acid analysis of Iberian pig fat by gas chromatography. Results of a mini collaborative study. Meat Sci 2002; 60:103-9. [DOI: 10.1016/s0309-1740(01)00166-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2000] [Revised: 05/11/2001] [Accepted: 07/25/2001] [Indexed: 12/01/2022]
|
33
|
Abstract
Methanolic extract of leaves and twigs of Guatteria cardoniana R.E. Fries (Annonaceae), a plant from the Venezuelan rain forest, was separated in alkaloid rich fractions and their biological effect on baby hamster kidney (BHK) cell line was studied. The initial plant extract (FA) induced cell proliferation, cytotoxicity as well as antiviral activity, depending on the concentration used. Further separation of this methanolic extract allowed us to separate these biological activities. The fraction with the highest antiviral activity (F7) was chromatographed and three of the nine alkaloid-rich fractions obtained, retained this activity. One of them (F(7)11) exhibited the highest inhibitory effect against a neurotropic Sindbis virus (NSV).
Collapse
Affiliation(s)
- A Paredes
- Laboratorio de Leprología y Patología Experimental, Instituto de Biomedicina, Facultad de Medicina, Universidad Central de Venezuela, 1010A, Caracas, Venezuela
| | | | | | | | | | | |
Collapse
|
34
|
Abstract
Although alphaviruses have been extensively studied as model systems for the structural organization of enveloped viruses, no structures exist for the phylogenetically distinct eastern equine encephalomyelitis (EEE)-Venezuelan equine encephalomyelitis (VEE) lineage of New World alphaviruses. Here we report the 25-A structure of VEE virus, obtained from electron cryomicroscopy and image reconstruction. The envelope spike glycoproteins of VEE virus have a T=4 icosahedral arrangement, similar to that observed in Old World Sindbis, Semliki Forest, and Ross River alphaviruses. However, VEE virus has pronounced differences in its nucleocapsid structure relative to nucleocapsid structures repeatedly observed in Old World alphaviruses.
Collapse
Affiliation(s)
- A Paredes
- National Center for Macromolecular Imaging, Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | |
Collapse
|
35
|
Abstract
Morphological studies of granular neurons of the hippocampus have shown that adrenalectomy (ADX) induces the cell death of granular neurons, an effect prevented by corticosterone replacement. We addressed the hypothesis that corticosterone regulates the expression of the apoptotic bcl-2 gene family. Five days after adrenalectomy, we observed morphological changes related to hippocampal granule cell apoptosis that was accompanied by terminal dUTP nick and labeling (TUNEL) labeling in nuclei located in the hilus region. Corticosterone replacement prevented the cell death induced by ADX. Using RT-PCR we found a reduction in mRNA levels of the antiapoptotic gene bcl-2 in whole hippocampus, an effect which was prevented by corticosterone administration to ADX rats. However, Bcl-2 protein levels were not altered by this treatment. We did not observe modifications in the level of bcl-X(L) mRNA however, we did find a 40% reduction in Bcl-X(L) protein levels, an effect not reversed by corticosterone. In contrast, we found a reduction in the mRNA of the antiapoptotic gene bax and Bax levels after ADX; both effects were prevented by corticosterone. The reduction in proapoptotic bax and in antiapoptotic bcl-2 mRNA levels in the whole hippocampus, suggests that local variations in these molecules could account for both neuronal viability of the CA1-CA3 and granular cell death detected by morphological means and observed after ADX.
Collapse
Affiliation(s)
- M Greiner
- Department of Biochemistry and Molecular Biology, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile, Santiago
| | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Bilger M, Heger S, Brann DW, Paredes A, Ojeda SR. A conditional tetracycline-regulated increase in Gamma amino butyric acid production near luteinizing hormone-releasing hormone nerve terminals disrupts estrous cyclicity in the rat. Endocrinology 2001; 142:2102-14. [PMID: 11316778 DOI: 10.1210/endo.142.5.8166] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Gamma amino butyric acid (GABA) is the main inhibitory neurotransmitter controlling LH-releasing hormone (LHRH) secretion in the mammalian hypothalamus. Whether alterations in GABA homeostasis within discrete regions of the neuroendocrine brain known to be targets of GABA action, such as the median eminence, can disrupt the ability of the LHRH releasing system to maintain reproductive cyclicity is not known but amenable to experimental scrutiny. The present experiments were undertaken to examine this issue. Immortalized BAS-8.1 astroglial cells were genetically modified by infection with a regulatable retroviral vector to express the gene encoding the GABA synthesizing enzyme glutamic acid decarboxylase-67 (GAD-67) under the control of a tetracycline (tet) controlled gene expression system. In this system, expression of the gene of interest is repressed by tet and activated in the absence of the antibiotic. BAS-8.1 cells carrying this regulatory cassette, and cultured in the absence of tet ("GAD on"), expressed abundant levels of GAD-67 messenger RNA and GAD enzymatic activity, and released GABA when challenged with glutamate. All of these responses were inhibited within 24 h of exposure to tet ("GAD off"). Grafting "GAD on" cells into the median eminence of late juvenile female rats, near LHRH nerve terminals, did not affect the age at vaginal opening, but greatly disrupted subsequent estrous cyclicity. These animals exhibiting long periods of persistent estrus, interrupted by occasional days in proestrus and diestrus, suggesting the occurrence of irregular ovulatory episodes. Administration of the tetracycline analog doxycycline (DOXY) in the drinking water inhibited GAD-67synthesis and restored estrous cyclicity to a pattern indistinguishable from that of control rats grafted with native BAS-8.1 cells. Animals carrying "GAD on" cells showed a small increase in serum LH and estradiol levels, and a marked elevation in serum androstenedione, all of which were obliterated by turning GAD-67 synthesis off in the grafted cells. Morphometric analysis of the ovaries revealed that both groups grafted with GABA-producing cells had an increased incidence of large antral follicles (>500 micrometer) compared with animals grafted with native BAS-8.1 cells, but that within this category the incidence of steroidogenically more active follicles (i.e. larger than 600 micrometer) was greater in "GAD on" than in "GAD off" rats. These results indicate that a regionally discrete, temporally controlled increase in GABA availability to LHRH nerve terminals in the median eminence of the hypothalamus suffices to disrupt estrous cyclicity in the rat, and raise the possibility that similar local alterations in GABA homeostasis may contribute to the pathology of hypothalamic amenorrhea/oligomenorrhea in humans.
Collapse
Affiliation(s)
- M Bilger
- Division of Neuroscience, Oregon Regional Primate Research Center/Oregon Health Sciences University, Beaverton, Oregon 97006, USA
| | | | | | | | | |
Collapse
|
38
|
Frazier KS, Paredes A, Dube P, Styer E. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol 2000; 37:328-35. [PMID: 10896394 DOI: 10.1354/vp.37-4-328] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Connective tissue growth factor (CTGF) has been shown to mediate many actions of transforming growth factor-beta (TGF-beta) in the fibrotic response in several diseases. We compared expression of CTGF, TGF-beta, platelet-derived growth factor (PDGF), TNF-alpha, and interleukin-1 (IL-1) by in situ hybridization in Sprague-Dawley rats euthanized at 0, 2, 4, and 8 weeks after 5/6 nephrectomy using the rat remnant kidney model of renal failure. Collagen was evaluated by trichrome stains, immunohistochemistry, and electron microscopy. We compared expression patterns to cells undergoing metaplasia. Tubular epithelial regeneration and transdifferentiation to myofibroblasts were assessed morphologically and by proliferating cell nuclear antigen, smooth muscle actin, desmin, and vimentin immunohistochemistry. CTGF expression was minimal in controls, mild at 2 weeks and marked by 4 to 8 weeks in interstitial fibroblasts, coinciding with damage, regeneration, and fibrosis. TGF-beta expression was increased in many cell types at 2 weeks, increased further by 4 weeks, then remained constant. PDGF-B messenger RNA was found in many stromal cells at 2-4 weeks, but expression decreased at 8 weeks. No significant IL-1 or TNF-alpha staining was detected. We conclude that CTGF and interacting factors are associated with development or progression of chronic interstitial fibrosis. Proximity of CTGF, TGF-beta, and PDGF mRNA expression to regenerative epithelial cells and those transdifferentiating to myofibroblasts suggests that growth factors may modulate renal tubular epithelial differentiation.
Collapse
Affiliation(s)
- K S Frazier
- College of Veterinary Medicine, Veterinary Diagnostic and Investigational Laboratory, The University of Georgia, Tifton 31793, USA.
| | | | | | | |
Collapse
|
39
|
Felip E, Rosell R, Alberola V, Gómez-Codina J, Maestre J, Astudillo J, Camps C, Gonzalez-Larriba JL, Moreno I, Paredes A, Artal A, García-Gómez R, Garrido P, Cardenal F, Barneto I, Sánchez JJ. Preoperative High-Dose Cisplatin Versus Moderate- Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. Clin Lung Cancer 2000; 1:287-93. [PMID: 14733634 DOI: 10.3816/clc.2000.n.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Preoperative chemotherapy has become an accepted treatment for stage IIIA (N2) non small-cell lung cancer (NSCLC). The majority of induction regimens employ cisplatin, although the importance of cis-platin dose in combination is unclear. A randomized trial was conducted to address whether higher pre-operative cisplatin doses result in improved survival and increased pathologic complete response in NSCLC. Patients with stage IIIA clinically enlarged and biopsy-proven N2 lesions were randomly assigned to receive either high-dose cisplatin (HDCP) (100 mg/m2) or moderate-dose cisplatin (MDCP) (50 mg/ m2) in combination with ifosfamide (3 g/m2) and mitomycin (6 mg/m2). Disease was restaged after 3 cycles, and those patients with response or stable disease underwent thoracotomy. From March 1993 to February 1997, 83 patients were randomized: 46 received HDCP, and 37 received MDCP. Clinical characteristics were well matched. Radiographic response rate was 59% for HDCP patients and 30% for MDCP patients (P = 0.01). Thoracotomy was performed in 71 patients (86%), 58 of whom had resectable disease. Complete resection rate was 61% in the HDCP group, and 51% in the MDCP group (P = 0.5). Postoperative mortality was 11%. Pathologic complete response was observed in one patient who received MDCP. Median survival in the HDCP and MDCP groups was 13 and 11 months, respectively (P = 0.3). In conclusion, higher radiographic response rate is observed in patients who receive HDCP, but this study fails to show any significant improvement in either overall survival or pathologic complete response in this group of patients.
Collapse
Affiliation(s)
- E Felip
- Hospital Vall d'Hebron, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Lara HE, Dissen GA, Leyton V, Paredes A, Fuenzalida H, Fiedler JL, Ojeda SR. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 2000; 141:1059-72. [PMID: 10698182 DOI: 10.1210/endo.141.3.7395] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A form of polycystic ovary (PCO) resembling some aspects of the human PCO syndrome can be induced in rats by a single injection of estradiol valerate (EV). An increase in sympathetic outflow to the ovary precedes, by several weeks, the appearance of cysts, suggesting the involvement of a neurogenic component in the pathology of this ovarian dysfunction. The present study was carried out to test the hypotheses that this change in sympathetic tone is related to an augmented production of ovarian nerve growth factor (NGF), and that this abnormally elevated production of NGF contributes to the formation of ovarian cysts induced by EV. Injection of the steroid resulted in increased intraovarian synthesis of NGF and its low affinity receptor, p75 NGFR. The increase was maximal 30 days after EV, coinciding with the elevation in sympathetic tone to the ovary and preceding the appearance of follicular cysts. Intraovarian injections of the retrograde tracer fluorogold combined with in situ hybridization to detect tyrosine hydroxylase (TH) messenger RNA-containing neurons in the celiac ganglion revealed that these changes in NGF/p75 NGFR synthesis are accompanied by selective activation of noradrenergic neurons projecting to the ovary. The levels of RBT2 messenger RNA, which encodes a beta-tubulin presumably involved in slow axonal transport, were markedly elevated, indicating that EV-induced formation of ovarian cysts is preceded by functional activation ofceliac ganglion neurons, including those innervating the ovary. Intraovarian administration of a neutralizing antiserum to NGF in conjunction with an antisense oligodeoxynucleotide to p75 NGFR, via Alzet osmotic minipumps, restored estrous cyclicity and ovulatory capacity in a majority of EV-treated rats. These functional changes were accompanied by restoration of the number of antral follicles per ovary that had been depleted by EV and a significant reduction in the number of both precystic follicles and follicular cysts. The results indicate that the hyperactivation of ovarian sympathetic nerves seen in EV-induced PCO is related to an overproduction of NGF and its low affinity receptor in the gland. They also suggest that activation of this neurotrophic-neurogenic regulatory loop is a component of the pathological process by which EV induces cyst formation and anovulation in rodents. The possibility exists that a similar alteration in neurotrophic input to the ovary contributes to the etiology and/or maintenance of the PCO syndrome in humans.
Collapse
Affiliation(s)
- H E Lara
- Laboratory of Neurobiochemistry, Faculty of Chemistry and Pharmaceutical Sciences, Universidad de Chile, Santiago
| | | | | | | | | | | | | |
Collapse
|
41
|
Dissen GA, Lara HE, Leyton V, Paredes A, Hill DF, Costa ME, Martinez-Serrano A, Ojeda SR. Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat. Endocrinology 2000; 141:1073-82. [PMID: 10698183 DOI: 10.1210/endo.141.3.7396] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A single injection of estradiol valerate induces a form of cystic ovary resembling some aspects of the human polycystic ovarian syndrome. Preceding the development of follicular cysts, there is an increase in intraovarian synthesis of nerve growth factor (NGF) and the low affinity NGF receptor (p75 NGFR). Selective blockade of NGF actions and p75 NGFR synthesis in the ovary restored estrous cyclicity and ovulatory capacity in estradiol valerate-treated rats, suggesting that an increase in NGF-dependent, p75 NGFR-mediated actions within the ovary contributes to the development of cystic ovarian disease. We have tested this hypothesis by grafting NGF-producing neural progenitor cells into the ovary of juvenile rats that have been induced to ovulate precociously by a single injection of PMSG. The NGF-producing cells, detected by their content of immunoreactive p75 NGFR material, were found scattered throughout the ovary with some of them infiltrating the granulosa cell compartment of large, precystic follicles. Ovarian NGF content was 2-fold higher than in the ovary of rats receiving control cells. Estrous cyclicity was disrupted, with the animals showing prolonged periods of persistent estrus, and an almost continuous background of vaginal cornified cells at other phases of the estrous cycle. Morphometric analysis revealed that the presence of NGF-producing cells neither reduced the total number of corpora lutea per ovary nor significantly increased the formation of follicular cysts. However, the ovaries receiving these cells showed an increased incidence of precystic, type III follicles, accompanied by a reduced number of healthy antral follicles, and an increased size of both healthy and atretic follicles. These changes in follicular dynamics were accompanied by a selective increase in serum androstenedione levels. The results show that an abnormally elevated production of NGF within the ovary suffices to initiate several of the structural and functional alterations associated with the development of follicular cysts in the rat ovary.
Collapse
Affiliation(s)
- G A Dissen
- Division of Neuroscience, Oregon Regional Primate Research Center-Oregon Health Sciences University, Beaverton 97006-3448, USA.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Boric MP, Figueroa XF, Donoso MV, Paredes A, Poblete I, Huidobro-Toro JP. Rise in endothelium-derived NO after stimulation of rat perivascular sympathetic mesenteric nerves. Am J Physiol 1999; 277:H1027-35. [PMID: 10484425 DOI: 10.1152/ajpheart.1999.277.3.h1027] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To evaluate whether sympathetic activity induces nitric oxide (NO) production, we perfused the rat arterial mesenteric bed and measured luminally accessible norepinephrine (NE), NO, and cGMP before, during, and after stimulation of perivascular nerves. Electrical stimulation (1 min, 30 Hz) raised perfusion pressure by 97 +/- 7 mmHg, accompanied by peaks of 23 +/- 3 pmol NE, 445 +/- 48 pmol NO, and 1 pmol cGMP. Likewise, perfusion with 10 microM NE induced vasoconstriction coupled to increased NO and cGMP release. Electrically elicited NO release depended on stimulus frequency and duration. Endothelium denudation with saponin abolished the NO peak without changing NE release. Inhibition of NO synthase with 100 microM N(omega)-nitro-L-arginine reduced basal NO and cGMP release and blocked the electrically stimulated and exogenous NE-stimulated NO peak while enhancing vasoconstriction. Blocking either sympathetic exocytosis with 1 microM guanethidine or alpha1-adrenoceptors with 30 nM prazosin abolished the electrically evoked vasoconstriction and NO release. alpha2-Adrenoceptor blockade with 1 microM yohimbine reduced both vasoconstriction and NO peak while increasing NE release. In summary, sympathetically released NE induces vasoconstriction, which triggers a secondary release of endothelial NO coupled to cGMP production.
Collapse
Affiliation(s)
- M P Boric
- Unidad de Regulación Neurohumoral, Departamento de Ciencias Fisiológicas, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
A 3-wk period of stress promotes the development of ovarian cysts in rats apparently mediated by increased sympathetic nerve activity and ovarian steroid secretion. After 11 wk of stress, these parameters are indistinguishable from nonstressed control rats. To study adrenal contribution, we adrenalectomized rats and studied the effect of 3-wk of cold/restraint stress (1.5 h/d) on them compared to intact animals. Adrenalectomy (ADX) increased ovarian norepinephrine (NE) release, the content of beta-adrenergic receptors (betaAR) and basal, but not isoproterenol (Iso)-induced, androgen secretion. Stress to intact animals increased NE release, decreased betaAR content, and Iso-induced, but not basal, androgen secretion from the ovary. ADX did not modify the response to stress. We propose a tonic inhibition by the adrenal gland on nerve activity of ovarian nerves. Stress overrides this inhibitory effect, and nerve activity downregulates betaAR, decreasing ovarian steroid secretion.
Collapse
Affiliation(s)
- A Gálvez
- Department of Biochemistry and Molecular Biology, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile
| | | | | | | | | |
Collapse
|
44
|
Abstract
Changes in psychosocial functioning, including depression, anxiety, somatization, obsessive-compulsiveness, interpersonal sensitivity, confidence in the ability to resist taking drugs in different situations, and social adjustment are examined for male veterans entering treatment for cocaine dependence. The sample was comprised of African Americans (66%), Hispanics (8%), and Whites (26%) with a mean age of 35 years at intake. Participants were assessed at the end of 1 year and 2 years; during the follow-up period, participants utilized different combinations of treatment modalities. Paired t-tests showed significant improvement between intake and follow-up, both at the end of 1 year and 2 years, on the Beck Depression Inventory, on the depression, anxiety, obsessive-compulsiveness, and interpersonal sensitivity scores of the Symptom Check List (SCL-58), and in four role areas of social adjustment on the Social Adjustment Inventory. There were no significant differences between intake and follow-up on the somatization subscale of the SCL-58 and on the Drug Taking Confidence Questionnaire (DTCQ). Measures taken at Year 2 were not significantly different from Year 1. Repeated measures analysis of variance revealed that treatment modality did not differentially affect psychosocial functioning on nearly all measures, except on somatization, confidence in the ability to resist taking drugs in different situations, and social adjustment involving leisure time. However, a combination of inpatient, high-intensity outpatient, and self-help group participation and a combination of outpatient and self-help group participation were better than a combination of inpatient, low-intensity outpatient, and self-help participation in increasing the confidence in the ability to resist cocaine use in different situations and to reduce symptoms of somatization.
Collapse
|
45
|
Sánchez Parra M, Churruca C, Paredes A, Lacasta A, López de Argumedo G, Alvárez I, Abad T, Egana L, Guimón E, Piera JM. Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. Am J Clin Oncol 1999; 22:6-7. [PMID: 10025370 DOI: 10.1097/00000421-199902000-00002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The association of ifosfamide with cisplatin and 5-fluorouracil for the management of advanced squamous cell carcinoma of the head and neck was assessed in this trial. Ifosfamide was given initially to 12 patients in combination with standard fixed doses of cisplatin and 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, and 4. Two patients died of neutropenia and severe infection, and the authors recruited seven more patients who were treated with a lower dose of ifosfamide, 800 mg/m2 daily on days 2, 3, and 4. One of the seven patients died of neutropenia and severe infection. Three complete remission were observed in 18 patients evaluable for efficacy. The study was closed early because of the severe toxicity profile demonstrated by this scheme and because of no clear advantage in efficacy versus cisplatin plus 5-fluorouracil combinations.
Collapse
Affiliation(s)
- M Sánchez Parra
- Medical Oncology Unit, Hospital Aránzazu, San Sebastian, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Paredes A, Gálvez A, Leyton V, Aravena G, Fiedler JL, Bustamante D, Lara HE. Stress promotes development of ovarian cysts in rats: the possible role of sympathetic nerve activation. Endocrine 1998; 8:309-15. [PMID: 9741836 DOI: 10.1385/endo:8:3:309] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Activation of the sympathetic innervation precedes the induction of polycystic ovaries in rats given estradiol valerate (EV). The mechanism of induction by EV may thus involve both direct and neurogenic components. We tested this hypothesis using a combined cold and restraint stress to induce an increase in sympathetic tone, including that of the ovarian sympathetic nerves. Three weeks after the start of stress we found: 1. An increase in the content of norepinephrine (NE) in the celiac ganglion. 2. An increase in the release of NE from the ovary. 3. An unchanged NE uptake by the ovary. 4. An unchanged content of NE in the ovary. The ovarian content of neuropeptide Y (NPY) (colocalized with NE) was significantly decreased. These results suggest that NE synthesis and its secretion are increased during this period and correlate with the increase in secretion of androgens and estradiol, the development of precystic follicles, and a decrease in the ovulatory rate. After 11 wk, NE release had returned to control values, whereas the ovarian NE content had risen significantly, suggesting a maintained high rate of NE synthesis. In the ovary, NPY contents, steroid secretion, morphology, and ovulation had returned to the control state. These results suggest the participation of an extraovarian factor that might act locally to control the release of NE from the ovary, and further support the hypothesis that increased sympathetic activity plays a role in the development and maintenance of ovarian cysts.
Collapse
Affiliation(s)
- A Paredes
- Department of Biochemistry and Molecular Biology, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile, Santiago
| | | | | | | | | | | | | |
Collapse
|
47
|
Kasarabada ND, Anglin MD, Khalsa-Denison E, Paredes A. Variations in psychosocial functioning associated with patterns of progression in cocaine-dependent men. Addict Behav 1998; 23:179-89. [PMID: 9573422 DOI: 10.1016/s0306-4603(97)00078-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study examined the relationship between patterns of progression of cocaine use and psychosocial functioning in a sample of cocaine-dependent men who were veterans. Four patterns of progression were examined: mild-severe, moderate-severe, mild-moderate-severe, and severe only. Analysis of variance and post hoc analysis with Duncan grouping revealed significant differences among cocaine users with different patterns of progression in terms of negativism, problem index for situations involving unpleasant emotions, problem index for situations involving urges, depression, somatic anxiety, and medical problems in the family. However, there were no significant differences on sensation seeking, confidence to resist taking cocaine in different situations, obsessive compulsiveness, somatization, attention deficit, and social adjustment. Cocaine users with a severe-only pattern of progression were significantly more dysfunctional than those with mild-moderate-severe progression in terms of negativism, problem index for situations involving unpleasant emotions, depression, and somatic anxiety. Cocaine users with mild-moderate-severe progression had significantly less somatic anxiety than those with mild-severe progression and had less negativism and a lower problem index for urges than those with moderate-severe progression. Logistic regression analysis revealed unique behavioral variables associated with different patterns of progression. The implications of these findings for treatment are discussed.
Collapse
|
48
|
Silva H, Jerez S, Paredes A, Salvo J, Rentería P, Ramírez A, Montes C. [Fluoxetine in the treatment of borderline personality disorder]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25:391-5. [PMID: 9477607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE This study evaluates the therapeutic effect of fluoxetine, a selective serotonin reuptake inhibitor, in borderline personality disorder. METHOD 46 patients with borderline personality disorder according to DSM-III-R and Diagnostic Interview for Borderlines (DIB-R) criteria, were given fluoxetine 20-60 mg for seven weeks. They were evaluated each week using Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning Scale (GAF), Hamilton Depression Rating Scale (HDRS) and a clinical Impulsivity Scale. RESULTS There were significant improvements in BPRS, HDRS, GAF and Impulsivity Scale from the first week of the treatment. These improvements continued until the seven week of treatment. The favourable outcome was not only due to the improvement in depression and impulsivity scores, but also to the decline of global psychopathology. CONCLUSIONS The data suggest that fluoxetine is an effective pharmacologic treatment for borderline personality disorder. These findings support the hypothesis of a 5-HT dysfunction in borderline personality disorder.
Collapse
Affiliation(s)
- H Silva
- Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Chile
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
This chapter presents (1) a review of several studies on the relationship between violent/aggressive behavior and the use of cocaine and/or the use of alcohol; and (2) findings from our study of cocaine-dependent men, illustrating deviant and violent behavior before and during cocaine addiction careers. As had been found in previous research, use of alcohol and cocaine seemed to increase the likelihood of the cocaine users in our sample engaging in deviant or violent behaviors. The extent of deviant or violent behavior, in our sample, during periods of cocaine use, periods of cocaine-alcohol use, periods of alcohol use only, and periods of abstinence for both alcohol and cocaine are discussed. Changes in the nature of the deviant or violent behaviors prior to and after the onset of cocaine addiction are also described.
Collapse
Affiliation(s)
- M E Denison
- Laboratory for the Study of Addictions, West Los Angeles Veterans Administration, California 90073, USA
| | | | | |
Collapse
|
50
|
Affiliation(s)
- P A Compton
- Los Angeles Addiction Treatment Research Center, CA, USA
| | | | | | | |
Collapse
|